Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
Indian generic drugmakers warn that a steep United States tariff on generic imports would raise costs for American consumers and test India’s export exposure.
- Donald Trump announced a tariff schedule for generic drug imports into the United States that escalates if companies do not establish manufacturing in the United States by August 2028.
- Indian pharmaceutical companies said the proposed tariffs would be hard to absorb because of dependence on global supply chains.
- Indian drugmakers warned that the tariff proposal would raise costs for American consumers.
What happened
Donald Trump announced a tariff schedule for generic drug imports into the United States. Generic drug imports would keep zero tariffs for two years, then face a 100% tariff for one year and 200% thereafter if companies do not establish manufacturing in the United States by August 2028.
Indian pharmaceutical companies warned that such tariffs would raise costs for American consumers and would be hard for Indian firms to absorb because of dependence on global supply chains.
UPSC can frame the issue around trade protectionism versus affordable access to medicines, the dependence of the United States on Indian generic drugs, and the policy and strategic implications for India’s pharmaceutical export sector.
Related dispatches
